Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Kodiak Sciences Inc. (KOD)

4.725   -0.165 (-3.37%) 03-24 12:38
Open: 4.8 Pre. Close: 4.89
High: 4.85 Low: 4.62
Volume: 254,619 Market Cap: 247(M)

Technical analysis

as of: 2023-03-24 12:02:18 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 7.47     One year: 8.76
Support: Support1: 4.61    Support2: 3.84
Resistance: Resistance1: 6.39    Resistance2: 7.5
Pivot: 5.56
Moving Average: MA(5): 4.96     MA(20): 5.79
MA(100): 7.13     MA(250): 7.78
MACD: MACD(12,26): -0.7     Signal(9): -0.6
Stochastic oscillator: %K(14,3): 3.3     %D(3): 6.6
RSI: RSI(14): 23.4
52-week: High: 12.8  Low: 4.61
Average Vol(K): 3-Month: 272 (K)  10-Days: 442 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ KOD ] has closed above bottom band by 11.7%. Bollinger Bands are 59.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.17 - 5.2 5.2 - 5.23
Low: 4.73 - 4.76 4.76 - 4.8
Close: 4.83 - 4.89 4.89 - 4.94

Company Description

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Headline News

Wed, 22 Mar 2023
Daily Markets: Sentiment Rebounds After JPMorgan (JPM) Shores Up First Republic - Nasdaq

Mon, 20 Mar 2023
North American Morning Briefing: Banking Sector -2- -

Fri, 17 Mar 2023
How Does Kodiak Sciences Inc (KOD) Stock Rank on Wall Street Friday? - InvestorsObserver

Fri, 10 Mar 2023
Federated Hermes Inc. Buys 246353 Shares of Kodiak Sciences Inc ... - MarketBeat

Thu, 09 Feb 2023
Kodiak Sciences Inc. (NASDAQ:KOD) insiders who sold US$12m worth of stock earlier this year are probably glad they did so as market cap slides to US$384m - Simply Wall St

Fri, 03 Feb 2023
BlackRock Increases Position in Kodiak Sciences (KOD) - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 52 (M)
Shares Float 32 (M)
% Held by Insiders 5.6 (%)
% Held by Institutions 82 (%)
Shares Short 1,550 (K)
Shares Short P.Month 1,500 (K)

Stock Financials

EPS -2.92
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 16.95
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -26.8
Return on Equity (ttm) -59.2
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -6.85
Qtrly Earnings Growth 0
Operating Cash Flow -210 (M)
Levered Free Cash Flow -157 (M)

Stock Valuations

PE Ratio -1.62
PEG Ratio -0.1
Price to Book value 0.27
Price to Sales 0
Price to Cash Flow -1.17

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.